Purpose: To review current practice in the use of Prostate Specific Antigen (PSA) testing and assess the overall risks and benefits of PSA testing for Adenocarcinoma of the Prostate, specifically in men under age 65, and those living with risk factors for the disease. Materials and Methods: An extensive literature review of PSA testing in various age groups was conducted with the goal being to review PSA screening trends and assess current recommendations regarding PSA Screening for Adenocarcinoma of the Prostate in various age groups, focusing on studies directed towards patients under the age of 65 and the long-term risks and benefits of PSA screening in the diagnostic algorithm. In order to reduce bias, we assessed our sources for variables such as reporting, measurement and/or selection bias. Our conclusions were then compared with current recommendations. Relevant studies with data compiled after 2004, centered around PSA screening in men under the age of 65 in general and specifically in men with risk factors for developing Adenocarcinoma of the Prostate were included. Editorials, newspaper articles and other non-scholarly and non-peer reviewed sources were automatically excluded.
McAninch, J.W. and Lue, T.F. (2013) Smith and Tanagho’s General Urology. 18th Edition.
[3]
Kumar, V., Abbas, A.K., Fausto, N. and Aster, J.C. (2010) Robbins and Cotran Pathologic Basis of Disease. Eighth Edition.
[4]
National Cancer Institute (2016) Surveillance Epidemiology and End Results Program (SEER). Cancer Stat Facts: Prostate Cancer 1975-2014.
https://seer.cancer.gov/statfacts/html/prost/html
[5]
Salinas, C.A., Tsodikov, A., Ishak-Howard, M. and Cooney, K.A. (2014) Prostate Cancer in Young Men: An Important Clinical Entity. National Review of Urology, 11, 317-323. https://doi.org/10.1038/nrurol.2014.91
[6]
Fleshner, K., Carlsson, S.V. and Roobol, M.J. (2017) The Effect of the USPSTF PSA Screening Recommendation on Prostate Cancer Incidence Patterns in the USA. National Review of Urology, 14, 26-37. https://doi.org/10.1038/nrurol.2016.251
[7]
Frendl, D., et al. (2016) Impact of Guidelines on Prostate Cancer Screening in a Population-Based Setting, 2000-2014: Preliminary Results from the First AUA Data Grant. Journal of Urology, 195, e543. https://doi.org/10.1016/j.juro.2016.02.131
[8]
Rosenberg, M., Crawford, D., Newmark, J. and Steiner, M. (2016) Use of PSA Screening Guidelines among Primary Care Physicians (Abstract MP39-01). Journal of Urology, 195, e541. https://doi.org/10.1016/j.juro.2016.02.126
[9]
Olsson, C., Anderson, A. and Kapoor, D. (2016) Initial Prostate Cancer Detection before and after United States Preventative Task Force Recommendation on Prostate Cancer Screening. Journal of Urology, 195, e542.
https://doi.org/10.1016/j.juro.2016.02.129
[10]
Hussein, S., Satturwar, S. and Van der Kwast, T. (2015) Young Age Prostate Cancer. Journal of Clinical Pathology, 68, 511-515.
https://doi.org/10.1136/jclinpath-2015-202993
[11]
Grubb, R.L., Pinsky, P.F., Greenlee, R.T., et al. (2008) Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: Update on Findings from the Initial Four Rounds of Screening in a Randomized Trial. BJU International, 102, 1524. https://doi.org/10.1111/j.1464-410X.2008.08214.x
[12]
Hoffman, R.M., Meisner, A.L.W., Arap, W., Barry, M., Shah, S.K., Zeliadt, S.B. and Wiggins, C.L. (2016) Trends in United States Prostate Cancer Incidence Rates and Stage, 1995-2012. Cancer Epidemiology Biomarkers Prevention, 25, 259-263.
https://doi.org/10.1158/1055-9965.EPI-15-0723
[13]
American Cancer Society (2018) Facts and Figures 2018. American Cancer Society, Atlanta. www.cancer.org
[14]
Brawley, O.W. (2012) Trends in Prostate Cancer in the United States. Journal of the National Cancer Institute. Monographs, 2012, 152-156.
https://doi.org/10.1093/jncimonographs/lgs035
[15]
Haas, G.P., Delongchamps, N., Brawley, O.W., Wang, C.Y. and de la Rosa, G. (2008) The Worldwide Epidemiology of Prostate Cancer: Perspectives from Autopsy Studies. Canadian Journal of Urology, 15, 3866-3871.
[16]
McDavid, K., Lee, J., Fulton, J.P., Tonita, J. and Thompson, T.D. (2004) Prostate Cancer Incidence and Mortality Rates and Trends in the United States and Canada. Public Health Reports, 119, 174-186.
[17]
Moyer, Virginia on Behalf of the USPSTF (2012) US Preventive Services Task Force Recommendation Statement: Screening for Prostate Cancer. Annals of Internal Medicine, 157, 120-134.
[18]
Lim, L.S., Sherin, K. and the ACPM Prevention Practice Committee (2008) Screening for Prostate Cancer in U.S. Men: ACPM Position Statement on Preventive Practice. American Journal of Preventive Medicine, 34, 164-170.
[19]
Murtaza, M., Salih, A.F., Illzam, E.M., Sharifa, A.M., et al. (2016) Prostate Cancer: Pathophysiology, Diagnosis, and Prognosis. IOSR Journal of Dental and Medical Sciences, 15, 122-126.
Hess, K.R., Varadhachary, G.R., Taylor, S.H., et al. (2006) Metastatic Patterns in Adenocarcinoma. Cancer, 106, 1624-1633. https://doi.org/10.1002/cncr.21778
[22]
Velcheti, V., Karnik, S., Bardot, S.F. and Prakash, O. (2008) Pathogenesis of Prostate Cancer: Lessons from Basic Research. The Ochsner Journal, 8, 213-218.
[23]
Loeb, S. and Catalona, W.J. (2014) The Prostate Health Index: A New Test for the Detection of Prostate Cancer. Therapeutic Advances Urology, 6, 74-77.
https://doi.org/10.1177/1756287213513488
[24]
Punnen, S., Pavan, N. and Parekh, D.J. (2015) Finding the Wolf in Sheep’s Clothing: the 4 Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer. Reviews in Urology, 17, 3-13.
[25]
Vickers, A.J., et al. (2010) Prostate Specific Antigen Concentration at Age 60 and Death or Metastasis from Prostate Cancer: Case-Control Study. British Medical Journal, 341, c4521. https://doi.org/10.1136/bmj.c4521
[26]
Marks, L.S., Fradet, Y., Deras, H., et al. (2007) PCA3 Molecular Urine Assay for Prostate Cancer in Men Undergoing Repeat Biopsy. Urology, 69, 532-535.
https://doi.org/10.1016/j.urology.2006.12.014
[27]
Deras, H., Aubin, S.M., Blasé, A., et al. (2008) PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome. Journal Urology, 179, 1587-1592.
https://doi.org/10.1016/j.juro.2007.11.038
[28]
Stephan, C., Jung, K., Semjonow, A., Schulze-Forster, K., Cammann, H., Hu, X., et al. (2013) Comparative Assessment of Urinary Prostate Cancer Antigen 3 and TMPRSS2: ERG Gene Fusion with the Serum [-2] Pro-Prostate Specific Antigen Based Prostate Health Index for Detection of Prostate Cancer. Clinical Chemistry, 59, 280-288.
[29]
Lin, D.W., Porter, M. and Montgomery, B. (2009) Treatment and Survival Outcomes in Young Men Diagnosed with Prostate Cancer: A Population Based Cohort Study. Cancer, 115, 2863-2871. https://doi.org/10.1002/cncr.24324
[30]
Lange, E.M., Salinas, C.A., Zuhike, K.A., Ray, A.M., Wang, Y., et al. (2012) Early Onset Prostate Cancer Has a Significant Genetic Component. Prostate, 72, 147-156.
https://doi.org/10.1002/cncr.24324
[31]
Lange, E.M., Johnson, A.M., Wang, Y., et al. (2014) Genome-Wide Association Scan for Variants Associated with Early-Onset Prostate Cancer. PLoS ONE, 9, e93436.
https://doi.org/10.1371/journal.pone.0093436
[32]
Al-Ahmadie, H.A., Tickoo, S.K., Olgac, S., et al. (2008) Anterior-Predominant Prostatic Tumors: Zone of Origin and Pathologic Outcomes at Radical Prostatectomy. American Journal of Surgical Pathology, 32, 229-235.
https://doi.org/10.1097/PAS.0b013e31812f7b27
[33]
Tomlins, S.A., Bjartell, A., Chinnaiyan, A.M., et al. (2009) ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice. European Urology, 56, 275-286. https://doi.org/10.1016/j.eururo.2009.04.036
[34]
Young, A., Palanisamy, N., Siddiqui, J., et al. (2012) Correlation of Urine TMPRSS2: ERG and PCA3 to ERG+ and Total Prostate Cancer Burden. American Journal of Clinical Pathology, 138, 685-696. https://doi.org/10.1309/AJCPU7PPWUPYG8OH
[35]
Narod, S.A., et al. (2008) Fusion in the ETS Gene Family and Prostate Cancer. British Journal of Cancer, 99, 847-851. https://doi.org/10.1038/sj.bjc.6604558
[36]
Roobol, M.J., Kerkhof, M., Schroder, F.H., et al. (2009) Prostate Cancer Mortality Reduction by Prostate Specific Antigen Based Screening Adjusted for Non-Attendance and Contamination in the European Randomized Study of Screening for Prostate Cancer (ERSPC). European Urology, 56, 584.
https://doi.org/10.1016/j.eururo.2009.07.018
[37]
Moore, C.M., Robertson, N.L., Arsanious, N., Middleton, T., et al. (2013) Image-Guided Prostate Biopsy using Magnetic Resonance Imaging-Derived Targets: A Systematic Review. European Urology, 63, 125.
https://doi.org/10.1016/j.eururo.2012.06.004
[38]
Siddiqui, M.M., Rais-Bahrami, S., Truong, H., Stamatakis, L., et al. (2013) Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy Significantly Upgrades Prostate Cancer versus Systematic 12-Core Transrectal Ultrasound Biopsy. European Urology, 64, 713-719. https://doi.org/10.1016/j.eururo.2013.05.059
[39]
Andriole, G.L., Crawford, D.E., Grub III, R.L., et al. (2012) Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow up. Journal of the National Cancer Institute, 104, 125-132. https://doi.org/10.1093/jnci/djr500
[40]
Schroder, F.H., et al. (2009) Screening and Prostate Cancer Mortality in a Randomized European Study. New England Journal of Medicine, 360, 1320-1328.
https://doi.org/10.1056/NEJMoa0810084
[41]
Andriole, G.L., Crawford, E.D., Grubb, R.L., et al. (2009) Mortality Results from a Randomized Prostate-Cancer Screening Trial. New England Journal of Medicine, 360, 1310. https://doi.org/10.1056/NEJMoa0810696
[42]
Schroder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L.J., et al. (2014) The European Randomized Study of Screening for Prostate Cancer—Prostate Cancer Mortality at 13 Years of Follow-Up. The Lancet, 384, 2027-2035.
https://doi.org/10.1016/S0140-6736(14)60525-0
[43]
Ries, L.A.G., Melbert, D., Krapcho, M., et al. (2007) SEER Cancer Statistic Review, 1975-2004. National Cancer Institute, Bethesda.
http://seer.cancer.gov/csr/1975_2004/
[44]
United States Preventive Services Task Force (2017) Draft Recommendation Statement Regarding Prostate Cancer Screening.
https://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/prostate-cancer-screening1
[45]
United States Preventive Services Task Force (2012) Prostate Cancer Screening.
[46]
Cooperberg, M.R., et al. (2010) Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer. Journal of Clinical Oncology, 28, 1117.
https://doi.org/10.1200/JCO.2009.26.0133
[47]
Carroll, P.R., Parsons, J.K., Andriole, G., Bahnson, R.R., et al. (2017) NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection.
[48]
Carter, B.H., Albertsen, P.C., Barry, M.J., Etzioni, R., et al. (2015) American Urological Association (AUA) Guideline. Early Detection of Prostate Cancer.
http://www.auanet.org
[49]
Talcott, J.A. (2015) In the Clinic: Prostate Cancer. Annals of Internal Medicine, ITC1-12. https://doi.org/10.7326/AITC201512010
[50]
Jemal, A., et al. (2015) Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. JAMA, 314, 2054-2061.
https://doi.org/10.1001/jama.2015.14905
[51]
Gaylis, F., et al. (2016) The Chance in Prostate Cancer Presentation and Diagnosis Coinciding with Screening Recommendations. Journal of Clinical Oncology, 34, 44.
[52]
Boyle, P. and Brawley, O.W. (2009) Prostate Cancer: Current Evidence Weighs against Population Screening. Cancer Journal Clinics, 59, 220-224.
https://doi.org/10.3322/caac.20025
